Your browser doesn't support javascript.
loading
Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).
Nicoll-Griffith, D A; Yergey, J A; Trimble, L A; Silva, J M; Li, C; Chauret, N; Gauthier, J Y; Grimm, E; Léger, S; Roy, P; Thérien, M; Wang, Z; Prasit, P; Zamboni, R; Young, R N; Brideau, C; Chan, C C; Mancini, J; Riendeau, D.
Afiliação
  • Nicoll-Griffith DA; Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Québec, Canada. deborah_nicoll_griffith@merck.com
Bioorg Med Chem Lett ; 10(23): 2683-6, 2000 Dec 04.
Article em En | MEDLINE | ID: mdl-11128651
Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx) were prepared by synthetic or biosynthetic methods. Metabolites include products of oxidation, glucuronidation, reduction and hydrolytic ring opening. Based on an in vitro whole blood assay, none of the known human metabolites of rofecoxib inhibits COX-1 nor contributes significantly to the inhibition of COX-2.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Inibidores de Ciclo-Oxigenase / Lactonas Limite: Animals / Humans Idioma: En Ano de publicação: 2000 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Inibidores de Ciclo-Oxigenase / Lactonas Limite: Animals / Humans Idioma: En Ano de publicação: 2000 Tipo de documento: Article